SYK · Stryker Corp
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted diluted EPS non-GAAP | $6.29 | Six Months | — |
| Adjusted effective income tax rate non-GAAP | 15.7% | Six Months | — |
| Adjusted gross profit non-GAAP | $8.18B | Six Months | — |
| Adjusted gross profit margin non-GAAP | 66% | Three Months | — |
|
|
|||
| Adjusted net earnings non-GAAP | $2.43B | Six Months | — |
| Adjusted operating income non-GAAP | $3.08B | Six Months | — |
| Sales growth in constant currency - Orthopaedics Total non-GAAP | 3.3% | Six Months | — |
| Organic net sales growth | 2.4% | Q1 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SYK
this stock
Stryker Corp
|
$126.45B | -8.4% | +11.2% | 34.2 | 1.8% |
|
ABT
Abbott Laboratories
|
$198.74B | -10.9% | +5.7% | 32.0 | 1.2% |
|
MDT
Medtronic plc
|
$115.17B | -6.3% | +8.4% | 24.1 | 1.1% |
|
BSX
Boston Scientific Corp
|
$68.44B | -51.1% | +12.5% | 19.1 | 1.9% |
|
EW
Edwards Lifesciences Corp
|
$51.85B | +5.5% | +11.5% | 51.7 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SYK | -1.7% | -7.5% | -11.6% | -1.1% | -8.4% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | -2.8% | -11.4% | -26.3% | -4.3% | -21.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.